These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1054 related items for PubMed ID: 15364753

  • 1. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
    Aquino SL, Fischman AJ.
    Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
    [Abstract] [Full Text] [Related]

  • 2. Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration.
    Aquino SL, Asmuth JC, Alpert NM, Halpern EF, Fischman AJ.
    J Comput Assist Tomogr; 2003 Sep; 27(4):479-84. PubMed ID: 12886128
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Staging non-small cell lung cancer with whole-body PET.
    Marom EM, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE, Herndon JE, Patz EF.
    Radiology; 1999 Sep; 212(3):803-9. PubMed ID: 10478250
    [Abstract] [Full Text] [Related]

  • 6. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease.
    Farrell MA, McAdams HP, Herndon JE, Patz EF.
    Radiology; 2000 Jun; 215(3):886-90. PubMed ID: 10831716
    [Abstract] [Full Text] [Related]

  • 9. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
    Margery J, Milleron B, Vaylet F, Grahek D, Lebeau B, Mangiapan G, Bonardel G, de Labriolle-Vaylet C, Meignan M, Carette MF, Talbot JN, Housset B.
    Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
    [Abstract] [Full Text] [Related]

  • 10. Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients.
    Wu Y, Li P, Zhang H, Shi Y, Wu H, Zhang J, Qian Y, Li C, Yang J.
    Int J Cancer; 2013 Jan 15; 132(2):E37-47. PubMed ID: 22890912
    [Abstract] [Full Text] [Related]

  • 11. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T, Altmayer S, Watte G, Zanon M, Basso Dias A, Henz Concatto N, Hoefel Paes J, Mattiello R, de Souza Santos F, Mohammed TL, Verma N, Hochhegger B.
    Eur Radiol; 2020 Jul 15; 30(7):3641-3649. PubMed ID: 32125513
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer: comparisons of clinical effectiveness in a randomized trial.
    Yi CA, Lee KS, Lee HY, Kim S, Kwon OJ, Kim H, Choi JY, Kim BT, Hwang HS, Shim YM.
    Cancer; 2013 May 15; 119(10):1784-91. PubMed ID: 23423920
    [Abstract] [Full Text] [Related]

  • 14. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose.
    Rege SD, Hoh CK, Glaspy JA, Aberle DR, Dahlbom M, Razavi MK, Phelps ME, Hawkins RA.
    Cancer; 1993 Jul 01; 72(1):82-90. PubMed ID: 8389668
    [Abstract] [Full Text] [Related]

  • 15. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
    Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, Choi JY, Kwon OJ, Shim YM, Kim S.
    Radiology; 2005 Sep 01; 236(3):1011-9. PubMed ID: 16014441
    [Abstract] [Full Text] [Related]

  • 16. Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer.
    Lardinois D, Weder W, Roudas M, von Schulthess GK, Tutic M, Moch H, Stahel RA, Steinert HC.
    J Clin Oncol; 2005 Oct 01; 23(28):6846-53. PubMed ID: 16192576
    [Abstract] [Full Text] [Related]

  • 17. Positron emission tomography/computed tomography in lung cancer staging, prognosis, and assessment of therapeutic response.
    Truong MT, Viswanathan C, Erasmus JJ.
    J Thorac Imaging; 2011 May 01; 26(2):132-46. PubMed ID: 21508735
    [Abstract] [Full Text] [Related]

  • 18. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.
    Cheran SK, Herndon JE, Patz EF.
    Lung Cancer; 2004 Jun 01; 44(3):317-25. PubMed ID: 15140545
    [Abstract] [Full Text] [Related]

  • 19. Value of FDG PET in the management of NSCLC.
    Ukena D, Hellwig D.
    Lung Cancer; 2004 Aug 01; 45 Suppl 2():S75-8. PubMed ID: 15552785
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.